Diane Healey

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

Matthew D. Hellmann, Tudor–Eliade Ciuleanu, Adam Płużański et al. · New England Journal of Medicine · 2018 · 3.1K citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)

Leora Horn, David R. Spigel, Everett E. Vokes et al. · Journal of Clinical Oncology · 2017 · 875 citations · Full text

Medicine, Oncology, Pharmacology +16

Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases

E.E. Vokes, Neal Ready, Enriqueta Felip et al. · Annals of Oncology · 2018 · 469 citations · Full text

Medicine, Oncology, Pharmacology +17

Phase II Study of the Anti-Cytotoxic T-Lymphocyte–Associated Antigen 4 Monoclonal Antibody, Tremelimumab, in Patients With Refractory Metastatic Colorectal Cancer

Ki Y. Chung, Ira Gore, Lawrence Fong et al. · Journal of Clinical Oncology · 2010 · 307 citations · Full text

Medicine, Oncology, Pharmacology +17

Randomized Phase II Study of BR96-Doxorubicin Conjugate in Patients With Metastatic Breast Cancer

Anthony W. Tolcher, Steven Sugarman, Karen A. Gelmon et al. · Journal of Clinical Oncology · 1999 · 268 citations

Medicine, Oncology, Pharmacology +17